Nairz, M. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kappaB-inducible immune pathways. Immunity 34, 61— Nemati, A. In reply to: queries regarding local erythropoietin injection in tibiofibular fracture healing. Neubauer, A.
Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Noakes, T. Tainted glory—doping and athletic performance. Obara, N. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Ogilvie, M. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts.
Ohh, M. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
Cell Biol. Omlor, G. Increased bone formation in a rabbit long-bone defect model after single local and single systemic application of erythropoietin. Acta Orthop. Osman, H. Effect of short-term erythropoietin therapy on insulin resistance and serum levels of leptin and neuropeptide Y in hemodialysis patients. Indian J. Palis, J. Primitive and definitive erythropoiesis in mammals. Functional analysis of erythroid progenitors by colony-forming assays.
Methods Mol. Paoletti, E. Update on erythropoietin treatment: should hemoglobin be normalized in patients with chronic kidney disease? Parsa, C. A novel protective effect of erythropoietin in the infarcted heart. Pastore, Y. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Pavkov, M.
Changing patterns of type 2 diabetes incidence among Pima Indians. Diabetes Care 30, — Percy, M. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis.
Plenge, U. Erythropoietin treatment enhances muscle mitochondrial capacity in humans. Pradeep, S. Erythropoietin stimulates tumor growth via EphB4. Cancer Cell 28, — Prunier, F. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells.
Heart Circ. Pugh, C. New horizons in hypoxia signaling pathways. Cell Res. Quaschning, T. Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. Rankin, E. Hypoxia-inducible factor-2 HIF Cell , 63— Rauner, M. Bone Miner. Recny, M. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin.
Identification of des-arginine erythropoietin. Reinhardt, M. Non-hematopoietic effects of endogenous erythropoietin on lean mass and body weight regulation. Obesity 24, — Robertson, C. Treatment of mild traumatic brain injury with an erythropoietin-mimetic peptide. Neurotrauma 30, — Rogers, H. T-cell acute leukemia 1 TAL1. Rolfing, J.
The osteogenic effect of erythropoietin on human mesenchymal stromal cells is dose-dependent and involves non-hematopoietic receptors and multiple intracellular signaling pathways. Stem Cell Rev. A single topical dose of erythropoietin applied on a collagen carrier enhances calvarial bone healing in pigs. Rundqvist, H. Activation of the erythropoietin receptor in human skeletal muscle.
Ruschitzka, F. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Sadamoto, Y. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Sakanaka, M. In vivo evidence that erythropoietin protects neurons from ischemic damage. Santner, W. A longitudinal VBM study monitoring treatment with erythropoietin in patients with Friedreich ataxia. Acta Radiol.
Short Rep. Sarrai, M. Bone mass density in adults with sickle cell disease. Semenza, G. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Shingo, T. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. Shiozawa, Y. Erythropoietin couples hematopoiesis with bone formation. PLoS One 5:e Singbrant, S. Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment.
Singh, A. Correction of anemia with epoetin alfa in chronic kidney disease. Sinkeler, S. Endogenous plasma erythropoietin, cardiovascular mortality and all-cause mortality in renal transplant recipients. Smith, C. Survey of the diet of Pima Indians using quantitative food frequency assessment and hour recall.
Diabetic Renal Disease Study. Smith, T. The human side of hypoxia-inducible factor. Socolovsky, M. Blood 98, — Soliz, J. Erythropoietin and the sex-dimorphic chemoreflex pathway. Sun, H. Erythropoietin modulates the structure of bone morphogenetic protein 2-engineered cranial bone. Tissue Eng. Part A 18, — Suresh, S. Erythropoietin modulates bone marrow stromal cell differentiation. Bone Res. Suzuki, N. Regulation of hypoxia-inducible gene expression after HIF activation. Erythropoietin production in neuroepithelial and neural crest cells during primitive erythropoiesis.
Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Takeda, K. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Tan, C. Organ distribution of erythropoietin messenger RNA in normal and uremic rats. Teng, R. Acute erythropoietin cardioprotection is mediated by endothelial response. Basic Res. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production.
Tsai, P. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. Tsuma, Y. Um, M. Us Renal Data System Van Der Meer, P.
Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. Vichinsky, E.
The morbidity of bone disease in thalassemia. Villa, P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. Villafuerte, F. Chronic mountain sickness: clinical aspects, etiology, management, and treatment. High Alt. Voss, J. Lower obesity rate during residence at high altitude among a military population with frequent migration: a quasi experimental model for investigating spatial causation.
Association of elevation, urbanization and ambient temperature with obesity prevalence in the United States. Wang, L. Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system. PPARalpha and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders.
Wassink, G. Partial white and grey matter protection with prolonged infusion of recombinant human erythropoietin after asphyxia in preterm fetal sheep. Watowich, S. The erythropoietin receptor: molecular structure and hematopoietic signaling pathways. Westenbrink, B. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Heart J.
Witthuhn, B. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74, — Wright, D. Association of erythropoietin dose and route of administration with clinical outcomes for patients on hemodialysis in the United States. Anemia can have many different causes, ranging from iron or vitamin deficiencies to decreased blood cell life span or excessive bleeding.
An erythropoietin test can help a doctor identify the underlying cause of anemia in people who do not seem to have iron or vitamin deficiencies. Doctors can also use erythropoietin tests when a person has a very high blood cell count.
This is a condition called polycythemia. The erythropoietin test can identify the underlying cause and help doctors determine the next step. Doctors may also order this test when investigating chronic kidney disease.
Erythropoietin tests may also help diagnose other conditions affecting the bone marrow , such as myeloproliferative disorders. Average erythropoietin levels are around 5. The average range can vary slightly depending on the laboratory conducting the test. Significant changes in erythropoietin levels may help doctors identify the underlying cause of the issue.
However, erythropoietin test results are not conclusive in every case, and doctors will often use other tests to help them identify and diagnose the underlying issue. Test results that show that a person with anemia has high erythropoietin levels may be a sign of a bone marrow disorder. Low or normal erythropoietin levels in a person with anemia may be a sign of kidney disease.
In people with polycythemia, meanwhile, an erythropoietin test can help doctors identify the next diagnostic tools they need to use. For instance, a person with polycythemia who has high erythropoietin levels may have a tumor or kidney condition causing them to produce too much erythropoietin. A person with polycythemia and normal or low erythropoietin levels may have polycythemia vera, which is a rare type of blood cancer. In any case, healthcare professionals will use additional tests to help clarify their results and confirm their diagnosis.
Blood transfusions using healthy, erythropoietin-rich blood may help treat some forms of anemia from chronic kidney failure. Sometimes, however, a blood transfusion is not possible. When this is the case, a doctor may recommend synthetic injections called erythropoietin-stimulating agents ESAs. Doctors can deliver these drugs through an injection that activates the bone marrow in the same way that natural erythropoietin does, stimulating red blood cell production.
This oxygen sensor has been recently shown to be an heme protein. At the Epo gene level, studies to identify cis-acting DNA sequences, and trans-activation factors for inducible kidney and liver Epo expression are being pursued. Abstract Erythropoietin Epo is a glycoprotein that promotes the proliferation and differentiation of erythrocyte precursors.
Erythropoietin is necessary for life in vertebrates. Mice that are homozygous for deletions of the erythropoietin gene die early in gestation from severe anemia. A common cause of erythropoietin deficiency is chronic kidney disease. When the kidneys are damaged, their ability to produce erythropoietin is compromised and anemia ensues.
The anemia associated with chronic kidney disease can be alleviated by treatment with erythropoietin. Such treatment is also valuable in a number of other types of disease associated with deficits in red blood cells production. Other Endocrine Tissues and Hormones.
0コメント